motor fluctuations over time, including periods of good symptom control (“on” time) mixed with troublesome involuntary movements (dyskinesia) or “off” periods. Traditional dopamine agonists, which mainly target D2 and D3 receptors, sometimes bring side effects such as excessive daytime sleepiness, impulse control issues, or swelling in the legs.
This is where the conversation gets interesting. What if a medication could focus more precisely on the pathways that support movement while potentially reducing some of those unwanted effects?
How Tavapadon Works: A Selective New Pathway
Tavapadon is an investigational once-daily oral